Key result
Hyperuricemia linked to up to ~135% higher metabolic syndrome risk in patients on lipid-lowering therapy.
Why the study?
Is elevated serum uric acid associated with metabolic syndrome and cardiovascular disease in Chinese patients on lipid-lowering therapy?
Population
15,478 Chinese patients aged ≥45 years treated with lipid-lowering agents from 122 centers
Comparison
Elevated serum uric acid levels / hyperuricemia vs Lowest category of serum uric acid (SUA) level
Design
Cross-sectional
Authors
Loading...
Should not yet change practice in lipid-lowering therapy; leaves open whether uric acid monitoring aids metabolic syndrome risk stratification.
Cross-Sectional (n=15,401)
Yes
Is elevated serum uric acid associated with metabolic syndrome and cardiovascular disease in Chinese patients on lipid-lowering therapy?
Effect estimate: OR 1.51 (men), OR 2.35 (women) (95% CI 1.30-1.74 (men), 2.00-2.75 (women))
Elevated serum uric acid levels are independently associated with metabolic syndrome, coronary heart disease, and heart failure in middle-aged and elderly Chinese patients receiving lipid-lowering therapy.
Tian et al. (2015) conducted a cross-sectional in Dyslipidemia (n=15,401). Hyperuricemia (highest category of serum uric acid) vs. Lowest category of serum uric acid was evaluated on Metabolic syndrome (NCEP-ATPIII criteria) (OR 1.51 (men), OR 2.35 (women), 95% CI 1.30-1.74 (men), 2.00-2.75 (women)). Hyperuricemia was significantly associated with a higher risk of metabolic syndrome compared to the lowest serum uric acid category in Chinese patients receiving lipid-lowering therapy (OR 1.51 in men, OR 2.35 in women).